Q4 2025 EPS Estimates for Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Cut by Zacks Research

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) – Zacks Research dropped their Q4 2025 earnings per share (EPS) estimates for Catalyst Pharmaceuticals in a research report issued to clients and investors on Wednesday, April 24th. Zacks Research analyst A. Chakraborty now expects that the biopharmaceutical company will post earnings per share of $0.65 for the quarter, down from their previous forecast of $0.66. The consensus estimate for Catalyst Pharmaceuticals’ current full-year earnings is $1.81 per share. Zacks Research also issued estimates for Catalyst Pharmaceuticals’ Q1 2026 earnings at $0.76 EPS and FY2026 earnings at $3.45 EPS.

A number of other equities analysts also recently issued reports on the company. StockNews.com upgraded Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, March 21st. Cantor Fitzgerald reiterated an “overweight” rating and set a $34.00 price target on shares of Catalyst Pharmaceuticals in a research report on Friday, March 22nd. TheStreet upgraded Catalyst Pharmaceuticals from a “c+” rating to a “b” rating in a research report on Tuesday, March 12th. HC Wainwright restated a “buy” rating and issued a $24.00 target price on shares of Catalyst Pharmaceuticals in a research report on Friday, March 1st. Finally, Citigroup assumed coverage on Catalyst Pharmaceuticals in a research report on Thursday, March 14th. They issued a “buy” rating and a $27.00 target price on the stock. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Catalyst Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $26.43.

Catalyst Pharmaceuticals Trading Down 2.9 %

Shares of CPRX stock opened at $14.68 on Thursday. The company has a market capitalization of $1.73 billion, a P/E ratio of 24.07, a P/E/G ratio of 0.81 and a beta of 0.89. The business’s 50 day moving average is $15.50 and its two-hundred day moving average is $14.61. Catalyst Pharmaceuticals has a 12-month low of $11.09 and a 12-month high of $17.76.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last posted its earnings results on Wednesday, February 28th. The biopharmaceutical company reported $0.49 EPS for the quarter, topping the consensus estimate of $0.45 by $0.04. The firm had revenue of $110.57 million for the quarter, compared to analyst estimates of $105.78 million. Catalyst Pharmaceuticals had a return on equity of 26.56% and a net margin of 17.93%.

Institutional Investors Weigh In On Catalyst Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Parkside Financial Bank & Trust acquired a new stake in Catalyst Pharmaceuticals during the fourth quarter worth $31,000. GAMMA Investing LLC increased its stake in Catalyst Pharmaceuticals by 72.9% during the first quarter. GAMMA Investing LLC now owns 1,942 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 819 shares during the last quarter. Nisa Investment Advisors LLC increased its stake in Catalyst Pharmaceuticals by 306.3% during the fourth quarter. Nisa Investment Advisors LLC now owns 5,079 shares of the biopharmaceutical company’s stock worth $85,000 after acquiring an additional 3,829 shares during the last quarter. Tower Research Capital LLC TRC increased its stake in Catalyst Pharmaceuticals by 84.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 6,184 shares of the biopharmaceutical company’s stock worth $104,000 after acquiring an additional 2,833 shares during the last quarter. Finally, Sherbrooke Park Advisers LLC acquired a new stake in Catalyst Pharmaceuticals during the third quarter worth $123,000. Institutional investors and hedge funds own 79.22% of the company’s stock.

Insider Activity at Catalyst Pharmaceuticals

In related news, Director David S. Tierney sold 25,000 shares of the stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $15.68, for a total value of $392,000.00. Following the completion of the sale, the director now owns 348,874 shares of the company’s stock, valued at $5,470,344.32. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 12.10% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.